KBC Group’s Praxis Precision Medicines PRAX Stock Holding History

KBC Group’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$239K	Hold	715	–	–	﹤0.01%	979
2026 Q1	$230K	Buy	715 +39	+6%	+$12.1K	﹤0.01%	932
2025 Q4	$199K	Buy	+676	New	+$126K	﹤0.01%	921

Other funds holding PRAX

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

KBC Group's PRAX Position: Q2 2026 in Review

KBC Group held its Praxis Precision Medicines (PRAX) position steady in Q2 2026 at 715 shares worth $239K. The position accounts for ﹤0.01% of the portfolio, ranked #979.

KBC Group first reported a position in PRAX in Q4 2025 and has held it in 3 quarters since. 309 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

KBC Group held 715 shares of Praxis Precision Medicines worth $239K as of Q2 2026.
KBC Group left its Praxis Precision Medicines share count unchanged in Q2 2026.
Praxis Precision Medicines made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #979 holding.
KBC Group first reported a position in Praxis Precision Medicines in Q4 2025 and has held it in 3 quarters since.
309 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.